Attached files

file filename
EX-99.1 - PHARMACYCLICS INCex991to8k07380_02072013.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 7, 2013
 
PHARMACYCLICS, INC.
(Exact name of registrant as specified in its charter)
     
Delaware
000-26658
94-3148201
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
     
995 E. Arques Avenue, Sunnyvale, California
94085-4521
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (408) 774-0330
 
 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 
 
Item 8.01.
Other Events.
 
On February 7, 2013, Pharmacyclics, Inc., a Delaware corporation (the “Registrant”), issued a press release announcing  that it intends to report its financial results for the three and sixth months ended December 31, 2012, after the NASDAQ Market closes on Thursday, February 14, 2013. The Registrant will conduct a conference call and audio webcast at 4:30 p.m. ET on that day.  Instructions for the call and webcast are included in the press release. A copy of the press release is attached as Exhibit 99.1.
 
 
The foregoing description is qualified in its entirety by reference to the Registrant’s Press Release dated February 7, 2013, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.


Item 9.01
Financial Statements and Exhibits.
 
(d)    Exhibits.
 
Exhibit No.
 
Description
99.1
 
 Press Release dated February 7, 2013.
     

 
 
 

 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
 
February 7, 2013
 
PHARMACYCLICS, INC.
 
 
By:
/s/ Joshua T. Brumm
 
Name: Joshua T. Brumm
 
Title: Executive Vice President, Finance


 
3

 

EXHIBIT INDEX
 
 
Exhibit No.
 
Description
99.1
 
 Press Release dated February 7, 2013.
     

 
 
 
4